Here are the 424B prospectus supplements from D. Boral ARC Acquisition I Corp. (BCAR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BCAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAR filings page.
D. Boral ARC Acquisition I Corp. files a proxy statement/prospectus for a Business Combination that contemplates issuance of up to 60,456,000 shares of Class A Ordinary Common Stock, 30,744,000 shares of Class B Super Common Stock and 14,100,000 warrants.
The filing describes a merger agreement to combine BCAR (to be domesticated into Delaware and renamed Exascale Labs Holdings Inc.) with Exascale Labs Inc., under which 50,000,000 shares of PubCo Common Stock are allocated as merger consideration among Exascale securityholders. The proxy/prospectus discloses that as of July 6, 2026 BCAR’s trust account held $290,025,825.19, estimates a per-share redemption value of approximately $10.36 for the meeting, and sets an Extraordinary General Meeting for July 29, 2026. The BCAR Board and Insiders (owning ~32.0%) recommend approval; closing remains subject to customary conditions including receipt of a minimum cash financing and Nasdaq conditional listing.